The Public Face of Sulzer Medica
Executive Summary
Sulzer Medica is one of Europe's leading medical device firms. But during the 1990s, though it grew nicely, it still trailed other, US-based multi-national device firms. That was because the company had struggled with product development and had no publicly-traded stock with which to acquire new businesses. Now fresh from a successful IPO, Suler is ready to play by a whole new set of rules.
You may also be interested in...
Two Independents Emerge in Orthopedics
The once consolidating orthopedic implant business is, if anything, going in the opposite direction, given the decisions this week by parents of two of the leading companies to create stand-alone companies of their orthopedic businesses. Bristol-Myers confirmed what had been rumored for months: that it will spin off its Zimmer orthopedics business into a public company rather than sell the company to some other player. Earlier, Sulzer announced that it plans to spin off its medical device business, Sulzer Medica, in response to pressure from a large investor who was concerned about the industrial giant's declining stock performance. But these individual deals also represent a surprising industry turnaround--the consolidation of two years ago has largely stabilized pricing, allowing independent companies to thrive once again.
Eisai Plots A Meticulous Path To CMS Coverage For Lecanemab
The company believes the Phase III Clarity AD results offer a high level of evidence that may convince the Centers for Medicare and Medicaid Services to change its stance on anti-amyloid antibodies for lecanemab.
Symptoms Change But Savings OTC Drugs Deliver For US Health Care Spending Continue Growing
Substantially more consumers in 2022 report sleep issues, allergies and skin problems than in 2018 while using quit smoking aids has dropped, according to CHPA’s latest “Value of OTC Medicines” survey. Average annual household spending on OTCs is $645.